Kos/Biovail: How a Mid-Cap Can Win in Primary Care
In May 2005 Kos Pharmaceuticals took over three of Biovail Corp's hypertension drugs plus most of its associated sales force, paying just 1.4 times 2004 sales-or roughly a fifth of what Biovail had paid for the same products less than five years ago. The deal draws attention to why the two mid-cap companies--similarly sized, and, until recently, with a similar business model--have fared so differently in primary care.
You may also be interested in...
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.
After putting two generics together and then getting the product approved for a new indication, NitroMed priced its new drug above expectations. But will the old-style pricing strategy hold up in a managed care world?
Shire's proposed $1.6 billion cash takeover of TKT answers investors' call for some deal-making action and pipeline diversification. But critics say Shire has paid over the odds for some risky programs in unfamiliar territory--rather like it did with BioChem.